JOHANNESBURG - Pfizer and its German vaccine partner, Bio-NTech, have signed a letter of intent with the Biovac Institute, a company partially owned by the South African government.
The deal will see Pfizer start producing its COVID-19 vaccine destined for African nations at a facility in Cape Town.
It is set to deliver more than 100-million doses annually, all of which will be distributed to over 50 member states of the African Union.
The financial terms of the agreement are yet to be disclosed.
Watch the video above for more details on this story.
This is a huge move and an important step to get vaccines into Africa. We’ve seen how the rest of the world is basically returning to ‘normal life’ as the majority have been vaccinated. Manufacturing/distributing from Biovac CPT will mean more 💉 for Africa. #VaccineRollout— Heidi Giokos (@HeidiGiokos) July 21, 2021